Sign in Subscribe
Pharmaceutical industry

Femta Pharmaceuticals Submits IND Application for FM101 to Treat Rheumatoid Arthritis

Strategic Insights

— 1 min read

Femta Pharmaceuticals, a company focused on developing innovative therapeutic monoclonal antibodies, has taken a significant step forward in its research efforts by submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), for patients with rheumatoid arthritis (RA). This application will initiate a clinical development program for FM101, which is part of a novel class of immune modulators that inhibit the action of the pro-inflammatory cytokine IL-6. Pre-clinical studies have demonstrated the efficacy and safety of FM101, with GLP toxicology studies showing it to be safe and well-tolerated at doses of up to 100mg/kg.

Key Takeaways:

  • Femta Pharmaceuticals has submitted an IND application to the FDA for FM101, a high-affinity, humanized monoclonal antibody against IL-6, to treat rheumatoid arthritis.
  • Pre-clinical studies have shown FM101 to be effective in inhibiting IL-6 both in vivo and in vitro, and GLP toxicology studies have demonstrated its safety and tolerability at doses up to 100mg/kg.
  • FM101 is part of a novel class of immune modulators that inhibit the action of the pro-inflammatory cytokine IL-6, which is a major player in the etiology of several inflammatory diseases.
  • Rheumatoid arthritis is a progressive and debilitating disease of unknown etiology, with an estimated prevalence of 1 to 2% worldwide, and an average annual incidence in the United States of 70 per 100,000 annually.
  • The disease has a significant economic impact, with an estimated cost of $128 billion per year in medical care and lost wages and productivity in the United States.

Statistics:

  • Estimated global prevalence of rheumatoid arthritis: 1 to 2%
  • Average annual incidence in the United States: 70 per 100,000 annually
  • Total number of Americans affected by RA: 1.3 million
  • Economic cost of RA in the United States: approximately $128 billion per year
  • Incidence of RA in women: two to three times greater than in men
  • Age of RA onset: 30-60 years, with 80% of cases occurring within this range

Sources:

  • Femta Pharmaceuticals press release
  • American College of Rheumatology publication on rheumatoid arthritis
  • National Institutes of Health publication on IL-6 and its role in inflammation
  • www.femtapharma.com

Read more